Analysis evaluates cost-effectiveness of EV + Pem for locally advanced or metastatic urothelial carcinoma, indicating potential benefits for US payers.
Objective Enfortumab vedotin plus pembrolizumab (EV + Pem) was recently approved in the United States as the new first-line standard of care for locally advanced or metastatic urothelial carcinoma (la/mUC). We assessed the cost-effectiveness of EV + Pem as first-line treatment for la/mUC from a US third-party payer perspective, using the most recent database lock (data cutoff: 8 August 2024) from the Phase III EV302/KEYNOTE-A39 study (NCT04223856).
No takes yet. Share an insight, caveat, or question.
Meng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: